Tuesday, November 17, 2026
RSS


← All Stories

Pharmaceutical

Werewolf Therapeutics and Ambros Therapeutics Join Forces: Implications for Oncology Investors

A strategic merger between Werewolf and Ambros Therapeutics aims to enhance oncology therapeutics, raising $150 million in the process.

Aug 21, 2026
Pharmaceutical

Bristol Myers Squibb's ZENBEXUS Approval: A Strategic Move in Oncology

Bristol Myers Squibb's ZENBEXUS receives FDA approval, marking a significant step in oncology and investor interest.

Aug 20, 2026
Pharmaceutical

Ultragenyx's GENGLYCOS Approval: A Game Changer for Rare Disease Therapies

Ultragenyx's recent FDA approval for GENGLYCOS signals a significant shift in rare disease treatments.

Aug 20, 2026
Pharmaceutical

Ultragenyx Pharma's Surge: FDA Approval for GENGLYCOS and Its Market Implications

Ultragenyx Pharma's shares jumped ~14% following FDA approval for GENGLYCOS, highlighting its potential in the gene therapy market.

Aug 20, 2026
Pharmaceutical

Moderna's Landmark Phase 3 Win: What It Means for MRNA and the Biotech Sector

Moderna's recent Phase 3 trial success has sent shockwaves through the biotech sector, propelling its stock and igniting investor interest.

Aug 20, 2026
Pharmaceutical

Merck's Breakthrough: Analysts React to Positive Drug Trial News

Analysts are optimistic about Merck's future after a 7.4% surge in shares following positive trial results.

Aug 19, 2026
Pharmaceutical

Amylyx Pharmaceuticals' 55% Surge: A Turning Point for Avexitide and Biotech Investors

Amylyx Pharmaceuticals saw a 55% surge following positive results from its avexitide trial, signaling strong investor confidence.

Aug 19, 2026
Pharmaceutical

Moderna's Historic Phase 3 Cancer Vaccine Triumph: What Investors Need to Know

Moderna's stock saw a significant surge following its Phase 3 cancer vaccine success, indicating a pivotal moment for investors.

Aug 19, 2026
Pharmaceutical

Curaleaf's Hostile Takeover Bid: A Game Changer for the Cannabis Industry

Curaleaf's $4/share bid for Aurora Cannabis could reshape the cannabis landscape, creating ripples across the US and Canadian markets.

Aug 18, 2026
Pharmaceutical

Hims & Hers Faces FTC Lawsuit: Implications for Telehealth Investors

Hims & Hers faces regulatory scrutiny, prompting a closer look at its telehealth business model and market sentiment.

Aug 18, 2026
Pharmaceutical

BioMarin's Strategic Acquisition: What It Means for Investors

BioMarin's $275M acquisition of Alesta Therapeutics could enhance its rare disease focus and shareholder value.

Aug 18, 2026
Pharmaceutical

Curaleaf's Hostile Bid for Aurora Cannabis: Implications for North American Cannabis Investors

Curaleaf's $4/share bid for Aurora Cannabis signals major changes in the cannabis sector, impacting investors across the US and Canada.

Aug 18, 2026